HEMOPHILIA B
Clinical trials for HEMOPHILIA B explained in plain language.
Never miss a new study
Get alerted when new HEMOPHILIA B trials appear
Sign up with your email to follow new studies for HEMOPHILIA B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a single gene shot free hemophilia b patients from regular infusions?
⭐️ CURE ⭐️ TerminatedThis trial tests a gene therapy called FLT180a in adults with hemophilia B, a condition where the body lacks a clotting protein. The therapy delivers a working gene to help the body produce its own clotting factor. A small group of participants will receive a single dose and be f…
Matched conditions: HEMOPHILIA B
Phase: PHASE1, PHASE2 • Sponsor: Spur Therapeutics • Aim: ⭐️ CURE ⭐️
Last updated Aug 02, 2026 00:00 UTC
-
Gene-Edited cells aim to stop bleeding in severe hemophilia b
Disease control TerminatedThis early-stage trial tests a one-time treatment called BE-101 for adults with severe hemophilia B. The therapy uses a person's own blood cells, modified with CRISPR gene editing, to continuously produce the missing clotting factor. The goal is to reduce or prevent bleeding epis…
Matched conditions: HEMOPHILIA B
Phase: PHASE1, PHASE2 • Sponsor: Be Biopharma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene Editing's lasting impact: a 10-Year safety watch
Knowledge-focused TerminatedThis study checks on people who previously received gene editing for hemophilia B or mucopolysaccharidosis (MPS) I or II. No new treatment is given; instead, participants are monitored for up to 10 years to see if any new health problems or worsening of existing conditions appear…
Matched conditions: HEMOPHILIA B
Sponsor: Sangamo Therapeutics • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC